Alzheimer’s disease diagnosis and treatment: Never too early, never too late

Dr Sonya Miller, Head of Medical Affairs at TauRx, and Professor Bjoern Schelter, CEO at GT Diagnostics and Chief Analytics Officer at TauRx.png 1

September is World Alzheimer’s Month. In this blog, Dr Sonya Miller and Professor Bjoern Schelter share expert insights into the progress made so far in the diagnosis and treatment of Alzheimer's disease (AD).

Dr Sonya Miller is Head of Medical Affairs and Medical Oversight Lead at TauRx, a global leader in Tau-based research in AD which has recently completed its latest phase three clinical trial researching, a potential treatment for Alzheimer’s disease and is part of the joint venture which created GTD.

Professor Bjoern Schelter is CEO of GT Diagnostics (GTD) which aims to change the dementia diagnostic landscape by developing much-needed digital tools to support early diagnosis and progression monitoring.


September is World Alzheimer’s Month but in the history of diagnosis and treatment of AD, 2023 will go down as a landmark year of progress.

Decades of painstaking research since the last, modest AD breakthrough in 2003 have culminated in three game-changing achievements in the battle against the disease: the licensing of new drugs that can slow progression; positive research results for other late-stage products targeting different aspects of the disease; and the launch of a new generation of powerful, patient-centred diagnostic tools and effective blood-based biomarkers.

Taken together, these scientific leaps forward hold out a genuine promise of life-enhancing advances for the 55 million people globally who are currently living with dementia, and for the estimated 139 million people who may have developed the condition by 2050.

Thanks to these transformative developments, it is now genuinely never too early and never too late to take effective action on AD and dementia.

Never too early

Until the recent advances in blood-based biomarkers and diagnostic apps, AD and dementia diagnosis was based on a battery of tests carried out by a range of specialists, from GPs and psychiatrists to geriatricians and neurologists.

Typically, testing at a memory clinic was followed up by putting a person through a CT, PET, or MRI scanner to capture an image of their brain. Given this complexity and cost, AD diagnosis has often tended to come too late or not at all. 

However, researchers have now successfully developed diagnostic tests that are simple to administer and allow the condition to be caught at much earlier stages in its progress. These are opening the way for effective treatment through a new generation of therapeutics.

It is now possible to download the new generation of smart psychometric aids to diagnosis as apps on a smartphone or tablet, from the Google Store or Apple Store. These new apps are transforming the speed, ease, objectivity, and efficacy of diagnosis, meaning that it is never too early to check for possible symptoms.

GT Diagnostic’s new well-being app, called HiPAL, was launched commercially this summer. Already available in the US, the UK, several European countries, and Malaysia, it is set to be released across most of the world shortly.

The app allows anyone who has worries about their cognitive health to monitor their status in the comfort of their own homes in just 3-5 minutes. It’s simple, efficient, and patient-friendly.

Crucially, AD patients have now had their voice heard through new research conducted by TauRx. The consultation confirms that they want an app that is accessible, isn’t confronting and does not cause upset in the event of poor test performance.

This is important as some tests are seen as too onerous and daunting for people with a degree of memory impairment. HiPAL meets all these important patient wishes, making the promise of ‘never too early’ to monitor cognitive health, a reality. 

At the same time, HiPAL’s professional counterpart, HiPAL Pro, was listed with the FDA in the United States at the end of August for use by clinicians and neurologists. Early feedback has been very positive.

In tandem with the apps, a new generation of blood-based biomarker tests is also helping to overcome those long-standing barriers to AD diagnosis, making the process as straightforward and accessible as the universal tests for common cancer screening. Again, this allows for much earlier intervention and potentially more effective treatment.

Never too late

If it is never too early to diagnose and take action on AD, the latest research achievements are showing that it is never too late to consider appropriate treatment pathways. In July, TauRx announced encouraging results from its Phase 3 LUCIDITY trial, which focused on finding a potentially effective treatment for AD, including people suffering from mild-to-moderate Alzheimer’s disease.

The trial was accessible for recipients at various stages of the disease, including mild cognitive impairment (MCI) due to AD, and mild-moderate AD. With a reassuring safety profile, the trial didn’t exclude participants who were overweight, hypertensive, diabetic or who had complex co-morbidities. This stands in contrast with many other treatments that have been progressed, which focus mainly on treating the mildest stage of diagnosable AD.

The emerging focus from researchers like TauRx is to develop a treatment that benefits people across all more stages of AD, including moderate AD, which means it will never be too late to diagnose and seek treatment. TauRx is now engaged with regulators worldwide to help contribute to the treatment options being brought to mainstream healthcare services globally.

The new diagnostic tools and biomarkers for AD enable much earlier testing. This allows people to make lifestyle adjustments that could help prevent a predisposition from becoming a full-blown condition in later life.

Discovering a cure for, or preventing the onset of, AD remains the ultimate ambition for medical researchers. However, the powerful combination of effective diagnostic tools and the latest generation of therapeutics means that it really is never too early and never too late to intervene in AD and dementia. That is a message of hope for the millions of people living with these conditions and for their families.


More news and updates 

Women In Biotech Mentoring Programme: Mentee experience – Alex Gajdosova

In this interview, Alex Gajdosova, an Investment Analyst at 4BIO Capital reflects on her inspiring career journey and her decision to participate in the BIA’s Women In Biotech Mentoring Programme as a mentee.

CEO Update - 25 September 2023

The government is introducing legislation to reverse the reinstatement of the 1.5% stamp tax charge on issues and certain transfer of shares to depositary receipts issuers and clearance services – so as, broadly, to preserve the position as before the Retained EU Law (Revocation and Reform) Act was passed.

Women In Biotech Mentoring Programme: mentee experience - Hilary Birrell

In this interview, we delve into the remarkable career journey of Hilary Birrell, a seasoned biochemist with 35 years of experience in clinical trial operations. She shares her motivation for becoming a mentee in the Women In Biotech Mentoring Programme and the invaluable insights gained from her mentor.

CEO Update - 18 September 2023

It was an honour to represent our sector at the first-ever meeting of the UK Biosecurity Leadership Council, chaired by Science Minister George Freeman MP. Looking around the table, it was clear to see that the UK’s strategic advantage in the responsible use of engineering biology is that we have a diverse and world-leading set of capabilities from pioneering science to regulation and thought leadership – and that we are small enough, and networked enough as a nation to get together in a room to set agendas and work plans at pace and scale that can be globally impactful.

Powering regional growth: the Cambridge cluster

Our burgeoning life sciences sector contributes £94 billion to the UK’s economy each year and employs over 280,000 people. But did you know that Cambridge as a region is home to one of the world’s most successful life sciences and biotechnology hubs?

Alzheimer’s disease diagnosis and treatment: Never too early, never too late

September is World Alzheimer’s Month but in the history of diagnosis and treatment of Alzheimer’s disease (AD), 2023 will go down as a landmark year of progress.

CEO Update - 11 September 2023

Last week, the UK scientists celebrated the rejoining Horizon Europe research programme. For research and the flow of talented scientists, it is undoubtedly a good thing that has taken too long to agree. The UK government press release was clear that “Horizon will give UK COMPANIES and research institutions unrivalled opportunities to lead global work to develop new technologies and research projects, in areas from HEALTH to AI”.

CEO Update - 4 September 2023

The MHRA team have had a very busy summer and have made an impressive impact on tackling the backlog of applications that has been concerning our sector. I know industry members on the MHRA Clinical Trials Task & Finish Group are looking forward to a further meeting this week to hear more about the impact of interventions the agency has put in place to eliminate backlogs.

CEO Update - 29 August 2023

I return from holiday to the news that Abcam, a key British life science company founded in 1998, is to be acquired by Danaher, bringing to a conclusion a headline-grabbing intervention this year by founder Jonathan Milner. Once again, this shows the global attractiveness of a global life science company built in the UK. Continue reading...

Member spotlight: Meet UCB

In this blog, Alistair shares insights into the history of UCB, the company’s journey since its inception in 1928 and how BIA membership has impacted the company’s growth.


More within